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Abstract
Background: Recently we identified nasopharyngeal epithelium specific protein 1 (NESG1) as a potential tumor suppressor
in nasopharyngeal carcinoma (NPC). The purpose of this study is to investigate the involvement of NESG1 in tumor
progression and prognosis of human NPC.
Methodology/Principal Findings: NESG1 protein expression in NPC was examined. Survival analysis was performed using
Kaplan-Meier method. The effect of NESG1 on cell proliferation, migration, and invasion were also investigated.
Results: NESG1 expression was downregulated in atypical hyperplasia and NPC samples compared to normal and squamous
nasopharynx tissues. Reduced protein expression was negatively associated with the status of NPC progression. Patients
with lower NESG1 expression had a shorter overall survival and disease-free time than did patients with higher NESG1
expression. Multivariate analysis suggested NESG1 expression as an independent prognostic indicator for NPC patient
survival. Proliferation, migration, and invasion ability were significantly increased in cell lines following lentiviral-mediated
shRNA suppression of NESG1 expression. Microarray analysis indicated that NESG1 participated in multiple pathways,
including MAPK signaling and cell cycle regulation. Finally, DNA methylation microarray examination revealed a lack of
hypermethylation at the NESG1 promoter, suggesting other mechanisms are involved in suppressing NESG1 expression in
NPC.
Conclusion: Our studies are the first to demonstrate that decreased NESG1 expression is an unfavorable prognostic factor
for NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is a malignant tumor arising
from the epithelial cells that line the nasopharynx. Annual NPC
incidence rates are less than 1 in 100,000 in most populations,
except in southern China, where 20-fold more cases are reported
[1]. Synergetic effects of viral infections, genetic alterations, and
environmental factors are believed to cause abnormal gene
expression which contributes to the development of NPC. Among
these changes, the activation of oncogenes and inactivation of
tumor suppressor genes may be key steps for initiating tumor
formation and development [2–7].
We previously compared normal human nasopharynx mucosa
and oral cavity mucosa of the soft palate using differential display
and identified full-length NESG1 (Accession number: NM_
012337.1; Official name:CCDC19) specifically expressed in
human nasopharynx and trachea [8]. In a subsequent investiga-
tion, we revised the open reading frame (ORF) sequence of
NESG1 and updated its version number from NM_012337.1 to
NM_012337.2 in the NCBI GeneBank database [9]. NESG1 was
found to be specifically expressed in the nasopharynx epithelium
and decreased or absent in NPC tissues and cell lines compared to
normal tissue. In addition, the levels of NESG1 protein were
significantly greater in the lower-grade NPC tissues versus higher-
grade NPC. Elevated expression of NESG1 in NPC cells not only
significantly decreased cell proliferation and G1-S phase transi-
tion, but also markedly inhibited cell migration, invasion, and in
vivo tumorigenesis. NESG1 also significantly regulated the expres-
sion of cell cycleregulators CCNA1 and p21. Our findings provided
evidence that NESG1 may act as a tumor suppressor in NPC [9].
In this study, we present further evidence that NESG1 protein is
downregulated in human NPC tissues and NPC cells compared to
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27887noncancerous nasopharynx tissues. We also show that reduced
protein expression of NESG1 is inversely associated with NPC
progression and poor prognosis. Downregulation of overexpressed
NESG1 in 2F4 NPC cells significantly regained cell proliferation,
migration, and invasion. Furthermore, NESG1 knockdown
elevated CCNA1 expression and suppressed p21 expression. Gene
expression profile analysis indicated that NESG1 participates in
multiple pathways, such as MAPK signaling and tight junction
formation regulation. Finally, an epigenetic evaluation of the
NESG1 promoter revealed a lack of methylation, suggesting
involvement of other mechanisms in NESG1 suppression during
NPC. Our studies firstly demonstrate that NESG1 as a potential
tumor suppressor is an unfavorable prognostic factor for NPC.
Results
Downregulated protein expression of NESG1 was
associated with NPC progression
We measured the protein expression levels of NESG1 in 8 NPC
cell lines, 3 NPC tissues, and 5 noncancerous nasopharynx samples
by western blot. Markedly reduced expression of NESG1 was
observed in NPC cell lines and tissues compared to noncancerous
nasopharynx samples (Figure 1A). Expression levels of NESG1 were
then measuredinsamplesof204archived paraffin-embeddedNPC,
74 normal nasopharynx, 40 squamous epithelium, and 35 atypical
hyperplasia using immunohistochemical staining (Figure 1B1–14).
NESG1 protein was highly expressed in normal and squamous
epithelium samples (P=0.732) compared to atypical hyperplasia
and NPC samples (P,0.001). Furthermore, NESG1 expression in
atypical hyperplasia samples was relatively higher than in NPC
samples (P=0.021)(Table 1). Further, we analyzed the relationship
between clinicopathologic characteristics and NESG1 expression
levels in individuals with NPC (Table 2). We did not find a
significant association of NESG1 expression levels with patient’s
age, sex, smoking status, family tumor history, patients from area, or
tumor size (T classification) in 204 NPC cases. However, we
observed that the reduced expression level of NESG1 was markedly
correlated with lymph node metastasis (N classification) (N0–N1 vs.
N2–N3) (P=0.005), distant metastasis (N classification)(P=0.024),
and clinical stage (I–II vs. III–IV) (P=0.003) in NPC patients.
Survival analysis
To investigate the prognostic value of NESG1 expression for
NPC, we assessed the association between protein levels and
patients’ survival using Kaplan–Meier analysis with the log-rank
test. In 204 NPC cases with prognosis information, we observed
that the level of NESG1 protein expression was significantly
correlated with overall survival, as patients with lower levels of
NESG1 expression had poorer survival (Figure 2A1) and shorter
disease-free survival duration (Figure 2A2) than those with higher
NESG1 expression (P,0.001). In addition, age, TNM classifica-
tion, and clinical stage were also significantly correlated with
patients’ survival (P=0.034, P,0.001, P=0.003, P,0.001, and
P,0.001 respectively). We performed multivariate analysis of the
levels of NESG1 protein expression adjusted for age, TNM
classification, and clinical stage of NPC patients to determine that
NESG1 expression was an independent prognostic factor for NPC
(P,0.001) (Table 3).
Reduced NESG1 expression increases proliferation of NPC
cells in vitro
To further confirm the biological function of NESG1, we used a
lentiviral vector containing shRNA to specifically target and stably
knock down NESG1 overexpressed in 2F4 NPC cells. Four stably
transfected cell clones were obtained (1C6, 2E6, 1C9, 1D10).
Decreased expression of NESG1 protein was confirmed by
western blotting in these 4 cells compared to those infected with
PLV-Ctr (Figure 3A). The 1C9 and 1D10 cells with significantly
reduced NESG1 protein expression were then chosen for further
experimentation.
We first examined the effect of decreased NESG1 expression on
NPC cell growth in vitro. Using MTT assays, we found that shRNA-
NESG1 infected 1C9 and 1D10 NPC cells had an elevated growth
rate to 2F4-PLV control cells over a seven day period (P,
0.001)(Figure 3B). These results were also consistent with clono-
genicity tests as 1C9 and 1D10 cells formed an increased number of
colonies (57.66764.967 and 61.83365.345) compared to 2F4-PLV
cells (20.50063.619) over a two-week period. This suggested that
NESG1 knockdown dramatically increased colony formation in
1C9 and 1D10 cells (P,0.001)(Figure 3C).
Knockdown of NESG1 promotes cell migration and
invasion
To further examine the effect of NESG1 on cell migration, 1C9
and 1D10 cells were cultured on a transwell apparatus. After 12-h
incubation, the percentage of migrated cells was significantly
increased in both 1C9 and 1D10 cell groups compared to the
NESG1-overexpressing 2F4-PLV cells (for both P,0.001) (Figure 4A).
We next analyzed cell invasiveness using a Boyden chamber coated
with Matrigel for 16-h incubation. Both 1C9 and 1D10 cells
exhibited significantly increased invasiveness compared to control
cells (for both P,0.001)(Figure 4B).
Suppression of NESG1 expression downregulates p21
and restores CCNA1 levels
In our previous investigation, overexpression of NESG1 pro-
moted the expression of tumor suppressor p21 while downregu-
lating cell cycle promoter CCNA1. We continued examination of
these two factors after knockdown of NESG1 in 1C9 and 1D10
NPC cells. Consistent with our prior results, expression of p21 was
downregulated while CCNA1 upregulated in 1C9 and 1D10 cells
compared to 2F4-PLV cells (Figure 4C).
NESG1-mediated pathways
We recently observed 2408 differentially expressed genes be-
tween NESG1-overexpressing 2F4 cells and NESG1-negative Ctr-C6
cells (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27318)
by microarray analysis [8]. Further, NESG1-mediated differential
expression of 1442 genes were used to conduct pathway analysis
against the KEGG database, each with an ‘‘_at’’ extension in probe
set IDs representing unique probe set sequences. Significant
pathways 1–10 are listed in Figure 5A (Table 4), which included
cell cycle regulators that had been partially validated [8]. Among
them, MAPK signaling was considered to be the most significant
pathway mediated by NESG1, especially given its role in cell
proliferation, cell migration, and invasion.
Expression validation of significant factors associated
with MAPK pathway
Using real-time PCR analysis, we examined the expression of 10
genes associated with NESG1-mediated MAPK pathway between
2F4 cells and C6-Ctr cells. With the exception of NTRK2, the
other 9 genes including NF1, MAP3K2, PRKCA, NRAS,
DUSP3, RAP1A, ATF2, MAPKAPK2, and GRB2 ($2 Fold or
#0.57 Fold) were closely matched the expression patterns from the
microarray results (Figure 5A) (Table 2). In addition, the protein
expression of four of these genes was further validated by western
NESG1 in NPC
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27887Figure 1. Gradual downregulation of NESG1 protein in normal nasopharynx tissues, atypical hyperplasia, and NPC samples A.
Western blot analysis indicated that NESG1 protein was significantly downexpressed in NPC tissues and NPC cells compared to noncancer
nasopharynx epithelial tissues. B. NESG1 expression was progressively decreased in atypical hyperplasia and NPC samples compared to normal
nasopharynx and squamous tissues. 1) NESG1 expression in squamous epithelium: 1–2: Strong expression, 3: Weak expression; 2) NESG1 expression
in normal epithelium: 4–5: Strong expression, 6: Positive expression, 7: Weak expression; 3) NESG1 expression in atypical hyperplasia tissue: 8: Strong
expression, 9–10: Weak expression; 4) NESG1 expression in NPC: 11: Strong expression, 12: Positive expression, 13: Weak expression, 14: Negative
expression.
doi:10.1371/journal.pone.0027887.g001
NESG1 in NPC
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and GRB2 were markedly downregulated while DUSP3 upregu-
lated in NESG1-overexpressing 2F4 cells compared to NESG1-
negative Ctr-C6 cells (Figure 5B).
No methylation of NESG1 promoter was observed in NPC
Due to a bioinformatics predicted CpG island in the NESG1
promoter (Figure S1), we conjectured that hypermethylation of
NESG1 might result in the suppressed expression of NESG1 in
NPC. We did not find any methylation modification in NESG1
promoter region in 17 NPC samples or 3 NPs using NimbleGen
DNA methylation microarrays (Figure 6A), which suggested that
reduced expression of NESG1 in NPC was not due to its promoter
methylation.
Discussion
Nasopharyngeal epithelium-specific gene NESG1 was initially
isolated from human normal nasopharynx mucosa using an
improved differential display approach, and its sequences was
submitted to the Genbank database by our research group in 1999
[8]. In a recent investigation, we updated the NESG1 ORF
sequence and studied its role in NPC cells. Our results preliminarily
suggested NESG1 function as a tumor suppressor in NPC [9].
In the present study, we presented additional support for this
notion as NESG1 protein was downregulated in human NPC
tissues and cells compared to noncancerous nasopharynx tissues by
western blot. Furthermore, we also found that protein expression
of NESG1 was progressively decreased in atypical hyperplasia and
cancer tissues compared to normal and squamous epithelium by
immunohistochemistry. These results were not only consistent
with our previous investigation [9], but also hinted that lost
expression of NESG1 was involved in the stages of initiation and
precancerous lesion of NPC.
We previously observed that reduced NESG1 protein levels
were inversely associated with lymph node metastasis and clinical
stage of NPC which suggested its downregulation favored the
development of NPC. However, due to the limited patient sample
size and the absence of clinical prognosis information, we did not
investigate the detailed correlation of NESG1 expression with
clinical features and prognosis of NPC. In this report, we used a
larger cohort of 204 patients with clinical prognosis information to
analyze this relationship. Similar to our previous results, we found
that decreased expression of NESG1 inversely correlated with
lymph node metastasis and clinical stage of NPC [9]. We further
observed that decreased NESG1 expression was correlated with
distant metastases and statistically lower in the M1 group compared
to the M0 group. Together these studies suggest downregulated
NESG1 levels play an unfavorable role in NPC pathogenesis, a
correlation which has not been previously reported.
Our investigation provides data that reduced NESG1 protein
expression is correlated with decreased NPC patient overall
survival. According to univariate analyses, overall survival was
Table 1. Gradual downregulation of NESG1 protein in atypical hyperplasia and NPC samples compared to normal nasopharynx
tissues.
Group Protein expression (n) P Value
Total Negative Weak Positive Strong S/N/A/C S/N A/N C/N A/C
S4 00 3 1 3 2 4
N 74 0 4 29 41 0.008* 0.732# 0.000# 0.000# 0.021#
A 35 0 12 19 4
C 204 26 87 67 24
*Kruskal Wallis Test;
#Mann-Whitney U Test; S: Squamous epithelium; N: Normal epithelium; A: Atypical hyperplasia epithelium; C: Cancer; n: Patient case.
doi:10.1371/journal.pone.0027887.t001
Table 2. Correlation between the clinicopathologic
characteristics and expression of NESG1 protein in NPC.
Characteristics n NESG1 (%) P
High
expression
Low
expression
Gender
Male 142 64 (45.1) 78 (54.9) 0.879
Female 62 27 (43.5) 35 (56.5)
Age (y)
$50 96 42 (43.8) 54 (56.2) 0.888
,50 108 49 (45.4) 59 (54.6)
Smoking
Yes 44 19 (43.2) 25 (56.8) 0.865
No 160 72 (45.0) 88 (55.0)
Family tumor history
Yes 11 8 (72.7) 3 (27.3) 0.063
No 193 82 (42.5) 111 (57.5)
Patients from area
Patients from zhongshan 34 13 (38.2) 21 (61.8) 0.454
Patients from non-zhongshan 170 78 (45.9) 92 (54.1)
T classification
T1–T2 146 70 (47.9) 76 (52.1) 0.117
T3–T4 57 20 (35.1) 37 (64.9)
N classification
N0–N1 107 58 (54.2) 49 (45.8) 0.005
N2–N3 97 33 (34.0) 64 (66.0)
Distant metastasis
Yes 14 2 (87.5) 12 (12.5) 0.024
No 190 89 (8.30) 101 (91.7)
TNM Clinical stage
I,II 91 37 (40.7) 54 (59.3) 0.003
III,IV 113 24 (21.2) 89 (78.8)
doi:10.1371/journal.pone.0027887.t002
NESG1 in NPC
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expression. Multivariate analyses showed that decreased expres-
sion of NESG1 alone could be a significant predictor of poor
prognosis for NPC patients. Our data are the first to report the
clinical significance of decreased NESG1 expression as an
unfavorable prognosis biomarker in NPC.
Figure 2. Reduced expression of NESG1 decreases the survival time and disease-free survival time of NPC patients A. 1. Lower levels
of NESG1 reduced the survival time of NPC patients; 2. Decreased NESG1 expression diminished the disease-free survival time of NPC patients.
doi:10.1371/journal.pone.0027887.g002
Table 3. Summary of univariate and multivariate Cox regression analysis of overall survival duration.
Parameter Univariate analysis Multivariate analysis
P HR 95%CI P HR 95%CI
Gender
Male vs. female 0.244 1.313 0.831–2.076
Age
$50 vs. ,50 years 0.034 1.543 1.033–2.305 0.034 1.554 1.034–2.336
Family tumor history
Yes vs. No 0.083 0.290 0.071–1.178
Smoking
Yes vs. No 0.282 1.289 0.811–2.047
Area
Zhongshan vs. Non-Zhongshan 0.161 0.702 0.428–1.151
Career
Employee of Government Vs. Non-Gonverment 0.842 0.912 0.371–2.247
Biotherapy
Yes vs. No 0.193 0.393 0.096–1.604
T classification
T1–T2 vs. T3–T4 0.000 2.209 1.462–3.338 0.007 2.004 1.209–3.321
N classification
N0–N1 vs. N2–N3 0.003 1.854 1.236–2.781 0.031 1.807 1.055–3.095
M classification
M0 vs. M1 0.000 6.051 3.264–11.220 0.000 4.006 2.093–7.664
Clinical stage
I–II vs. III–IV 0.000 2.656 1.566–4.505 0.758 0.887 0.415–1.897
NESG1 expression
High expression vs. Low expression 0.000 0.189 0.112–0.317 0.000 0.244 0.143–0.418
doi:10.1371/journal.pone.0027887.t003
NESG1 in NPC
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suppress cell proliferation, migration, invasion, and cell cycle
progression [9], thus we further examined the biological functions
of NESG1 in NPC. We used a loss-of-function approach to knock
down the overexpressed NESG1 in 2F4 NPC cells, and confirmed
its role in promoting cell proliferation, migration, and invasion in
vitro. These results are consistent with our previous investigation
[9]. Our studies strongly suggest a suppressive role of NESG1 in
the development of NPC.
To fully understand the molecular mechanism of NESG1-
mediated suppressive pathways in NPC, we analyzed differential
expression ofNESG1-regulatedgenesagainstthe pathway-collected
database KEGG. Our computational pathway analysis of 1442
differentially expressed genes strongly supported that multiple
biological signaling pathways were involved in NESG1-mediated
NPC oncogenesis including MAPK, insulin, actin cytoskeleton,
focal adhesion, and cell cycle progression. In our recent report,
NESG1 altered expression of cell cycle regulators CCNA1 and p21,
a findingweconfirmedthroughaninverse approach.Wefoundthat
inhibition of NESG1 could markedly restore expression of cell cycle
promoting CCNA1 while downregulating tumor suppressor p21.
The mitogen-activated protein kinase (MAPK) cascade is a
highly conserved module that is involved in various cellular
functions, including cell proliferation [10–11], differentiation [12]
migration [13], and invasion [14,15]. MAPK was considered to be
an important pathway regulated by NESG1 based on its ranking
after computer analysis. Real-time PCR was used to validate the
differential expression patterns of MAPK pathway-associated
genes from the microarray results. Expression of NF1, MAP3K2,
PRKCA, NRAS, DUSP3, RAP1A, ATF2, MAPKAPK2, and
GRB2 were consistent with the microarray, which suggested that
NESG1 participated in the regulation of MAPK pathway in NPC.
Four of these relevant genes including ATF2 [16], MAPKAPK2,
DUSP3, and GRB2 were selected for further analysis. ATF2
encodes a transcription factor that is a member of the leucine
zipper family of DNA-binding proteins. In response to stress
stimuli, it activates a variety of gene targets including cyclin A,
cyclin D and c-jun, which participate in the oncogenesis of various
tissue types. ATF2 expression has been correlated with mainte-
nance of a cancer cell phenotype [17,18]. MAPKAPK2 is
regulated through direct phosphorylation by p38 MAP kinase.
In conjunction with p38 MAP kinase, this kinase is known to be
involved in many cellular processes including stress and inflam-
matory response [19], cell cycle regulation [20] and proliferation
[21]. A recent report indicated that MAPKAPK2 could mediate
p38 mitogen-activated protein kinase (MAPK) activation to drive
invasion of bladder cancer by inducing the expression of MMP-2
and MMP-9 [22]. The protein encoded by DUSP3 is a member of
the dual specificity protein phosphatase subfamily, which are
associated with cellular proliferation and differentiation. Upregu-
lated expression and nuclear localization of DUSP3 promotes the
pathogenesis of cervix carcinoma [23]. Loss of the expression can
cause cell-cycle arrest and senescence, which was dependent on
the hyperactivation of the mitogen-activated protein (MAP) kinases
Figure 3. Suppression of NESG1 restores growth and clone formation of NPC5-8F-2F4 cells. A. Expression of NESG1 was suppressed in
1C6, 2E6, 1C9 and 1D10 clones compared to 2F4-PLV cells by western blot. B. In vitro proliferative ability of NPC cells was significantly restored in
NESG1-suppressed 1C9 and 1D10 clones compared to NESG1-overexpressing 2F4-PLV cells by MTT assay. C. Downregulation of NESG1 markedly
increased the clone formation. Data are presented as mean6SD for three independent experiments. (*P,0.05).
doi:10.1371/journal.pone.0027887.g003
NESG1 in NPC
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or knock-down. Grb2 knockdown reduced mitogen-activated
protein kinase (MAPK) activity in BCR-ABL-expressing hemato-
poietic cells [25]. Tyrosine phosphorylation of Grb2 is taken as a
critical mechanism by which PRL antagonizes EGF-induced cell
proliferation by attenuating the activation of the Ras/mitogen-
activated protein kinase (MAPK) pathway [26]. Consistent with our
microarray results, ATF2, MAPKAPK2, and GRB2 weremarkedly
downregulated while DUSP3 upregulated in NESG1-overexpress-
ing 2F4 NPC cells compared to NESG1-negative C6-Ctr cells. Our
results suggested a novel mechanism where dysregulated NESG1
participates in the regulation of MAPK pathway in nasopharynx
carcinogenesis.
The hypermethylation of CpG islands in gene promoters can
often lead to transcriptional silencing of genes, including tumor
suppressor genes [27–30]. Due to the existence of predicted CpG
islands in the NESG1 promoter region, we used a NimbleGen DNA
methylation microarray to assess its methylation status in 17 NPC
casesand 3NPsamples.However,therewerenosignificantchanges
in NESG1 promoter methylation observed in these samples,
suggesting other mechanisms are involved in the repression of
NESG1 in NPC.
In summary, our present study provides additional support that
NESG1 functions as a tumor suppressor in NPC. Its decreased
expression level as an unfavorable important prognostic factor was
negatively correlated with the malignant status of NPC patients.
Our findings not only further support that NESG1 regulates cell
cycle factors, but also implicate its involvement in the MAPK
pathway during NPC oncogenesis. Increased promoter methyla-
tion can not account decreased NESG1 expression in NPC, thus a
different mechanism is likely responsible for its loss.
Materials and Methods
Cell culture, tissue collection and Ethics Statement
Eight (8) NPC cell lines including 5-8F, 6-10B, CNE2, CNE1,
C666-1, HONE1, HNE1, and SUNE1 [7] [9] were maintained in
RPMI 1640 supplemented with 10% newborn calf serum (NBCS)
(PAA Laboratories, Inc, Austria). Three (3) freshly isolated
primary NPC tissues, 5 freshly isolated non-cancerous nasophar-
ynx tissues, 204 paraffin-embedded undifferentiated NPC speci-
mens and 149 paraffin-embedded non-cancerous nasopharynx
specimens (including 74 normal epithelium, 40 squamous
epithelium, and 35 atypical hyperplasia epithelium) were obtained
at the time of diagnosis before any therapy from People’s Hospital
in Zhongshan City, Guangdong, China. In the 204 NPC cases,
there were 116 male and 48 female with age ranging from 17 to 76
years (median, 48.98 years). The clinical follow-up time of patients
Figure 4. Reduced NESG1 expression promotes cell migration and invasion in vitro.A .Downregulated NESG1 dramatically enhanced the
ability of 1C9 and 1D10 cell migration in vitro. B. Downregulated NESG1 markedly elevated in vitro invasiveness of 1C9 and 1D10 cells. C. Suppressing
NESG1 expression significantly increased the endogenous protein expression of CCNA1 and reduced the expression of p21 in 1C9 and 1D10 cells.
Data were presented as mean6SD for three independent experiments. (*P,0.05).
doi:10.1371/journal.pone.0027887.g004
NESG1 in NPC
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materials for research purposes, prior written informed consent
from all the patients (One patient aged 17 also gave consent for
himself) and approval from the Ethics Committees of People’s
Hospital of Zhongshan City were obtained. All specimens had
confirmed pathological diagnosis and were staged according to the
1997 NPC staging system of the WHO.
Western blot
Nasopharynx or NPC tissues were ground in liquid nitrogen
and lysed in RIPA buffer on ice containing protease inhibitors.
Cells were directly lysed in RIPA buffer. Protein lysates were
resolved on 10% SDS polyacrylamide gel, electro-transferred to
polyvinylidene fluoride membranes (Invitrogen, Carlsbad, CA,
USA), and blocked with 5% nonfat dry milk in Tris-buffered
saline, pH 7.5. Membranes were immunoblotted overnight at 4uC
with anti-NESG1 polyclonal antibody (Proteintech Group, Inc.
Chicago, IL, USA) or p21, anti-b-actin antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or CCNA1, ATF2,
MAPKAPK2, GRB2, DUSP3 (Abcam, Landon), followed by
their respective HRP-conjugated secondary antibodies. Signals
were detected using enhanced chemiluminescence reagents
(Pierce, Rockford, IL, USA).
Immunohistochemistry
Examination of NESG1 expression in samples of undifferenti-
ated NPC and nasopharynx tissues by IHC was performed as
previously described [9]. The stained tissue sections were reviewed
and scored independently by two pathologists blinded to the
clinical parameters. The staining score standard has also been
described [9]. For statistical analysis of NESG1 expression in
noncancerous tissues against NPC tissues, the staining score of 0,
1,2, 3,4, and 5,6 were respectively considered to be negative,
low, medium, and strong expression. For the correlated statistical
analysis of NESG1 expression with clinical features and prognosis
of NPC patients, the staining score of 0,4 and 5,6 were
respectively considered to be low and high expression.
Establishment of stable knock down clones with shRNA-
NESG1 from NESG1-expressing NPC 2F4 cell line
Two sequences were selected for targeting the NESG1 gene
using the BLOCK-It RNAi Designer (Invitrogen, Carlsbad, CA):
NESG1 509 (Sense: 59-CGCGTCCCCGCGGCAGAAATCC-
ATTCAAAGTTCAAGAGACTTTGAATGGATTTCTGCCG-
CTTTTTGGAAAT-39 and Antisense: 59-CGATTTCCAAAA-
AGCGGCAGAAATCCATTCAAAGTCTCTTGAACTTTGA-
ATGGATTTCTGCCGCGGGGA-39) and NESG1 1622 (Sense:
59-CGCGTCCCCGCATTGAAGCTGAGCGCAAAGTTCAA-
GAGACTTTGCGCTCAGCTTCAATGCTTTTTGGAAAT-39
and Antisense: 59-CGATTTCCAAAAAGCATTGAAGCTGA-
GCGCAAAGTCTCTTGAACTTTGCGCTCAGCTTCAATG-
CGGGGA-39). The preparation of lentiviral vectors expressing
human NESG1 short hairpin RNA (shRNA) was performed using
the pLVTHM-GFP Lentiviral RNAi Expression System [31]
supplied by Prof. Guangfei Xiao who worked in our cancer
institute. Replication-incompetent lentivirus was produced by
cotransfection of the pLVTHM/NESG1-shRNA expression
vector and ViraPower packaging mix containing an optimized
mixture of two packaging plasmids, psPAX2 and pMD2G, into
293FT cells. NPC NESG1-overexpressing 2F4 cells were infected
with lentiviral particles containing specific or negative control
vectors and the single colony with strong GFP expression was
Figure 5. Overexpressed NESG1 regulate the gene expression of MAPK pathway in NPC cells. A. Using real-time PCR to validate the
differential gene expression of MAPK pathway, DUSP3 ($2 Fold), NF1, MAP3K2, PRKCA, NRAS, RAP1A, ATF2, MAPKAPK2, and GRB2 (#0.57 Fold) in
NPC 2F4 cells relative to control NPC C6 cells. B. Protein expression of ATF2, MAPKAPK2, DUSP3, and GRB2 were consistent with differential
expression of mRNA level in NESG1-overexpressing NPC 2F4 cells compared to control NPC C6 cells.
doi:10.1371/journal.pone.0027887.g005
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these cell clones was isolated, and the levels of NESG1 protein
were measured using western blot assays.
MTT assay
The rate of in vitro cell proliferation was assessed using 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay. Cells were seeded in 96-well plates at a density of 1,000
cells/well. The cells were incubated for 1, 2, 3, 4, 5, 6, or 7 d.
Twenty microliters of MTT (5 mg/ml)(Sigma, St. Louis, MO) was
added to each well and incubated for 4 h. At the end of
incubation, the supernatants were removed, and 150 ml of DMSO
(Sigma, St. Louis, MO) was added to each well. The absorbance
value (OD) of each well was measured at 490 nm. For each
experimental condition, 8 wells were used. Experiments were
performed three times.
Colony formation assay
Cells were plated in 6-well culture plates at 100 cells/well. Each
cell group had 2 wells. After incubation for 9 days at 37uC, cells
were washed twice with PBS and stained with the Giemsa solution.
The number of colonies containing $50 cells was counted under a
microscope. The colony formation efficiency was calculated as
(number of colonies/number of cells inoculated)6100%.
Cell migration and invasion assays
For the cell migration assay, 1610
5 cells in 100 ml RPMI 1640
medium without NBCS were seeded on a fibronectin-coated
polycarbonate membrane insert in a transwell apparatus (Costar,
MA). In the lower chamber, 600 ml RPMI 1640 with 10% NBCS
was added as chemoattractant. After the cells were incubated for
12 h at 37uC in a 5% CO2 atmosphere, the insert was washed
with PBS, and cells on the top surface of the insert were removed
with a cotton swab. Cells adhering to the lower surface were fixed
with methanol, stained with Giemsa solution, and counted under a
microscope in five pre-determined fields (6200). All assays were
independently repeated at least three times. For the cell invasion
assay, the procedure was similar to the cell migration assay, except
that the transwell membranes were pre-coated with 24 mg/ml
Matrigel (R&D Systems, USA) and the cells were incubated for
16 hours at 37uC in a 5% CO2 atmosphere. Cells adhering to the
lower surface were counted the same way as for the cell migration
assay.
NESG1-mediated pathways in NPC by analyzing gene
expression profile data between NESG1-overexpressed
2F4 cells and NESG1-negative Ctr-C6 cells
Gene expression profiles were determined using Affymetrix
Human Genome U133 Plus 2.0 Array containing 47,000 tran-
scripts (Affymetrix, Santa Clara, CA) between NESG1-overex-
pressed 2F4 cells and control Ctr-C6 cells using significance
analysis of microarray (SAM) as described previously [9]. NESG1-
mediated pathways were analyzed against KEGG database by
MAS2.0 software (CapitalBio, Inc, Beijing, China).
Real-time PCR
The mRNA levels of MAPK signaling regulators NF1,
MAP3K2, PRKCA, NRAS, DUSP3, RAP1A, NTRK2, ATF2,
MAPKAPK2, and GRB2 in C6-Ctr and 2F4 cells were measured
using real-time PCR. ARF5, an invariant housekeeping gene in
nasopharynx and NPC samples, was used as internal control [9].
The primer pair sequences for these genes (Table S1) designed
spanned at least an intron to distinguish possibly amplified
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PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27887products from genomic DNA. The PCR reaction was carried out
using SYBR Green Mix reagent (Takara Inc, Japan). Real-time
PCR was repeated three times.
Examination of NESG1 promoter methylation by DNA
methylation microarray assay
The examination procedure of NimbleGen DNA methylation
microarray has been described [32]. Briefly, genomic DNA of 17
biopsy NPC samples containing more than 75% of tumor cells and
3 noncancerous nasopharynx epithelium tissues (NPs) was extracted
using DNeasy Blood & Tissue Kit (Qiagen, Inc.). Subsequently, all
DNA samples were used to perform MeDIP assay as described.
MeDIP DNA was utilized to hybridize to NimbleGen C4226-00-01
promoter-tiling arrays that were designed based on the HG18
genome release. All experiments were performed at the Kangchen
Biology Corporation, Shanghai, China.
Statistical analysis
All data were analyzed for statistical significance using SPSS
13.0 software. The Kruskal Wallis Test was used to examine the
differences of NESG1 expression among squamous epithelium,
normal epithelium, atypical hyperplasia, and cancer tissues of
nasopharynx. Mann-Whitney U test was employed to analyze the
differences of NESG1 expression between two groups in squamous
epithelium, normal epithelium, atypical hyperplasia, and cancer
tissues of nasopharynx. Chi-square test was applied to analyze the
relationship between NESG1 expression levels and clinicopatho-
logic characteristics. Survival analysis was performed using
Kaplan-Meier method. Multivariate Cox proportional hazards
method was used for analyzing the relationship between the
variables and patients’ survival time. One-way ANOVA was used
to determine the differences between groups for all in vitro analyses.
A P value of less than 0.05 was considered statistically significant.
Supporting Information
Figure S1 Prediction of CpG island in NESG1 promoter.
A. CpG island of NESG1 was predicted by methyl primer express
software1.0 in promoter sequence of NESG1 containing the first
exon 21 bp and its upstream 5048 bp. The results showed a CpG
island locating the first exon and its upstream 513 bp.
(TIF)
Table S1 Differential expression folds of MAPK path-
way genes between NESG1-overexpressed NPC 2F4 cells
and NESG1-negative NPC C6 cells and their primer pair
sequences.
(DOC)
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